Clinical Trial Update: A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen [Phase 2]

View source ↗

Summary

Phase 2 trial comparing ARQ 197 (tivantinib) against investigator's choice second-line chemotherapy for locally advanced or metastatic gastric cancer has been w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• ARQ 197 (tivantinib)

Snippet

Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Conditions: Gastric Cancer | Phase 2 | Status: WITHDRAWN